Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine for symptomatic frequent premature atrial complexes
IRCT20230618058519N1Phase 3Completed
- Sponsor
- Tehran Heart Center
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ivabradine and metoprolol in atrial extrasystole (AES) (2 arms), sponsored by Tehran Heart Center. Primary endpoints: Frequency of premature atrial complexes in 24-hour ECG Holter and Symptoms of symptomatic frequent premature atrial complexes. Started Jul 2023; status: completed.
02
Drugs
ivabradinemetoprolol
03
Conditions
atrial extrasystole (AES)
Beyond the preview
Go deeper on IRCT20230618058519N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230618058519N1.